| Jul 30 |
Fractyl gets FDA breakthrough device status for Revita
|
| Jul 30 |
IPO Roundup: Pershing Square, Actuate Therapeutics and more
|
| Jul 30 |
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
|
| Jul 28 |
Wall Street Breakfast: The Week Ahead
|
| Jun 25 |
FDA expands Fractyl endoscopy trial to include untreated diabetes patients
|
| Jun 25 |
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
|
| Jun 24 |
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
|
| Jun 23 |
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association...
|
| May 29 |
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
|
